Loading
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Previous close
$10.60
+$0.08 · +0.76%
Regular session · ET · Market data may be delayed.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Day range
Current $10.60
52-week range
Current $10.60
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
88
Deep Value
Sentiment
53
Mixed
Risk
39
Moderate Risk
Momentum
64
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Day range
Current $10.60
52-week range
Current $10.60
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 67.48M USD | 53.88M USD | — | — | — |
| Cost of goods sold | 57K USD | — | 849K USD | — | — |
| Gross profit | 67.43M USD | 53.88M USD | −849K USD | — | — |
| Research and development | 251.07M USD | 169.97M USD | 115.24M USD | 92.81M USD | 84.72M USD |
| Selling, general, and administrative | 119.98M USD | 77.11M USD | 50.57M USD | 47.05M USD | 46.54M USD |
| Operating expenses | 371.06M USD | 247.08M USD | 164.96M USD | 139.87M USD | 131.26M USD |
| Interest income | 26.77M USD | 22.85M USD | 14.72M USD | 4.25M USD | 1.21M USD |
| Interest expense | 1.51M USD | 1.62M USD | 1.55M USD | 229K USD | 414K USD |
| Depreciation and amortization | 1.03M USD | 848K USD | 849K USD | 759K USD | 558K USD |
| Operating income | −303.63M USD | −193.2M USD | −165.8M USD | −139.87M USD | −131.26M USD |
| Net income | −278.67M USD | −173.98M USD | −152.63M USD | −135.84M USD | −130.47M USD |
Company facts updated Oct 12, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$23.88
125.28% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI35.41M0.00%2.3T USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI27.1M0.27%9.87B USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM23.53M0.03%78.74B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF13.07M0.01%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO8.25M0.06%13.92B USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB7.09M0.07%10.82B USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO6.19M0.03%18B USD0.06%$112.66+0.50%
Fidelity Enhanced Small Cap ETFFESM5.55M0.08%6.41B USD0.28%$45.46+0.46%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
